Hematologic Effects of Linezolid: Summary of Clinical Experience

著者: Stanton L. Gerson, Sheldon L. Kaplan, Jon Bruss, Vu Le, Félix Arellano, Barry Hafkin, David J. Kuter - Antimicrobial Agents and Chemotherapy 2002 被引用: 443

Linezolid has been associated with reversible myelosuppression. Clinical trial data were evaluated for anemia, thrombocytopenia, and neutropenia. Thrombocytopenia and a slight increased risk for anemia were evident at > or =2 weeks of linezolid treatment. Hematologic abnormalities were consistent with mild, reversible, duration-dependent myelosuppression. Appropriate monitoring is warranted with linezolid use.